NCT06961565View on ClinicalTrials.gov

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
NF1 MutationNeurofibroma PlexiformNeurofibroma, PlexiformNeurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)Neurofibromatosis Type 1 (NF1)
Interventions
DRUG

PAS-004 Tablets

A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1m and 4mg strength tablets, intended for oral administration once daily.

Trial Locations (4)

2065

RECRUITING

Royal North Shore Hospital, St Leonards

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

6164

RECRUITING

Severance Hospital, Yonsei University Health System, Sinchŏn-dong

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Pasithea Therapeutics Corp.

INDUSTRY

NCT06961565 - PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter